Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,710 | 5 | 68.5% |
| Unspecified | $1,124 | 10 | 28.4% |
| Food and Beverage | $124.99 | 1 | 3.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $2,710 | 5 | $0 (2021) |
| GlaxoSmithKline, LLC. | $1,124 | 10 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $124.99 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,124 | 10 | GlaxoSmithKline, LLC. ($1,124) |
| 2022 | $124.99 | 1 | Janssen Pharmaceuticals, Inc ($124.99) |
| 2021 | $2,710 | 5 | Genentech USA, Inc. ($2,710) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $470.09 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $169.56 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $167.49 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $102.65 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $90.95 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $42.19 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $41.50 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $31.56 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $4.71 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $3.25 | Research |
| Study: A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | ||||||
| 04/07/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/14/2021 | Genentech USA, Inc. | Xofluza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $440.00 | General |
| Category: Virology & Specialty Care | ||||||
| 12/14/2021 | Genentech USA, Inc. | Xofluza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $190.00 | General |
| Category: Virology & Specialty Care | ||||||
| 11/17/2021 | Genentech USA, Inc. | Xofluza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Virology & Specialty Care | ||||||
| 09/29/2021 | Genentech USA, Inc. | Xofluza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Virology & Specialty Care | ||||||
| 01/28/2021 | Genentech USA, Inc. | Xofluza (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Virology & Specialty Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | GlaxoSmithKline, LLC. | $1,124 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 5 | 574 | 596 | $23,200 | $17,095 |
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 302 | 321 | $12,519 | $7,447 | 59.5% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 110 | 111 | $4,884 | $4,872 | 99.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 120 | 122 | $3,172 | $2,404 | 75.8% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2020 | 21 | 21 | $2,079 | $1,962 | 94.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2020 | 21 | 21 | $546.00 | $410.75 | 75.2% |
About Matthew Macsweeney, FNP, RN
Matthew Macsweeney, FNP, RN is a Registered Nurse healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1366609638.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Matthew Macsweeney, FNP, RN has received a total of $3,959 in payments from pharmaceutical and medical device companies, with $1,124 received in 2023. These payments were reported across 16 transactions from 3 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2,710).
As a Medicare-enrolled provider, Macsweeney has provided services to 574 Medicare beneficiaries, totaling 596 services with total Medicare billing of $17,095. Data is available for 1 year (2020–2020), covering 5 distinct procedure/service records.
Practice Information
- Specialty Registered Nurse
- Other Specialties Family
- Location Bronx, NY
- Active Since 05/22/2008
- Last Updated 08/05/2022
- Taxonomy Code 163W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1366609638
Products in Payments
- Xofluza (Drug) $2,710
- INVEGA SUSTENNA (Drug) $124.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Registered Nurse Doctors in Bronx
Robert Pintauro, Agpcnp-C, AGPCNP-C
Registered Nurse — Payments: $19,344
Shanti Marshall
Registered Nurse — Payments: $4,702
Mallory Woods, Np, NP
Registered Nurse — Payments: $4,472
Mrs. Sari Sloane, Anp-Bc, ANP-BC
Registered Nurse — Payments: $3,408
Brenda Mintz, Fnp, FNP
Registered Nurse — Payments: $3,365
Ariana Aquino, Np, NP
Registered Nurse — Payments: $2,885